Table 3. Multivariate analysis of clinical factors for 5-year overall survival (OS) and lung metastasis-free survival (LMFS) in the training set.
| Variable | 5-year PS (n = 340) | 5-year LMFS (n = 303) | ||||||
|---|---|---|---|---|---|---|---|---|
| β-value | RR | 95% CI | P-value | β-value | RR | 95% CI | P-value | |
| Enneking stage | 0.766 | 2.151 | 1.373–3.370 | 0.001 | - | - | - | - |
| Tumor size | 0.595 | 1.814 | 1.154–2.851 | 0.010 | 0.960 | 2.612 | 1.721–3.966 | <0.001 |
| Neutrophil × 109 | 0.480 | 1.617 | 1.024–2.552 | 0.039 | 0.445 | 1.561 | 1.011–2.408 | 0.044 |
| Platelet × 109 | 0.482 | 1.619 | 1.060–2.473 | 0.026 | 0.467 | 1.595 | 1.091–2.330 | 0.016 |
| ALP | 1.421 | 4.140 | 1.907–8.987 | < 0.001 | 0.551 | 1.736 | 1.084–2.779 | 0.022 |
OS: overall survival; LMFS: lung metastasis-free survival; ALP: alkaline phosphatase.